1)Kokubo Y, et al:Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease;The Suita Study. Stroke 40:2674-2679, 2009
2)ONTARGET Investigators:Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008
3)Agodoa LY, et al:Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001
4)Mann JF, et al:Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk(the ONTARGET study);A multicentre, randomised, double-blind, controlled trial. Lancet 372:547-553, 2008
5)TRANSCEND Investigators:Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors;A randomised controlled trial. Lancet 372:1174-1183, 2008
6)Mann JF, et al. Effect of telmisartan on renal outcomes:a randomized trial. Ann Intern Med 151:1-10, 2009
7)Jamerson K, et al:Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417-2428, 2008
8)Bakris GL, et al:Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events(ACCOMPLISH);A prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173-1181, 2010
9)ASTRAL Investigators:Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361:1953-1962, 2009